In acknowledgement of this year’s World Diabetes Day, which calls on all those responsible for diabetes care to understand diabetes and take control, Medtronic, Inc. (NYSE: MDT) highlights the growing body of clinical evidence for Personal Continuous Glucose Monitoring (CGM) in improving glucose control for diabetes patients.
Recent studies continue to suggest that the more often patients use Personal CGM, the greater average glucose control (A1C) they can achieve without increasing hypoglycemia (low blood sugar). Moreover, evidence is mounting for a variety of patients, including those with A1C levels above and below 7 percent, patients moving directly from multiple daily injections (MDI) to Personal CGM, and children using Personal CGM at the onset of their diagnosis. Personal CGM is approved for use by people ages 7 and older in the U.S. and for people of all ages in Canada. Medtronic offers separate Personal CGM devices for U.S. pediatric and adult patients.
“It’s very exciting to see the evidence unfold for Personal CGM,” said Francine Kaufman, M.D., chief medical officer and vice president, global medical, clinical and health affairs at Medtronic Diabetes. “World Diabetes Day reminds us to acknowledge favorable evidence and incorporate tools into daily practice to improve patients’ lives.”
Personal CGM reveals fluctuations in glucose levels that often go unnoticed when only standard fingerstick measurements are used. By viewing continuous data and trend graphs, patients can react to high or low glucose levels before they become dangerous. Additionally, this information can help provide insights into the underlying causes of glucose fluctuations, allowing for therapy adjustments to be made to help improve patients’ overall health and quality of life.
Six key studies suggesting the benefits of Personal CGM are described below:
GuardControl Trial (162 patients, Ages 8-59): The purpose of this study was to understand whether poorly-controlled type 1 patients (A1C levels ≥8.1 percent) previously treated with intensive insulin therapy (insulin pump therapy or MDI) could improve glucose control using Personal CGM. The study revealed a >1 percent A1C reduction in half the subjects and ≥2 percent in 26 percent of the subjects after three months of near daily Personal CGM use.
STAR 1 Trial (146 Patients, Ages 12-72): This trial evaluated the safety and efficacy of an insulin pump with Personal CGM compared to an insulin pump alone in subjects with type 1 diabetes already using insulin pump therapy. It is the most prolific glucose sensor accuracy study ever published with more than 60,000 paired data points. The data provide evidence that increased glucose sensor usage enhanced the probability of A1C reduction.